Alterity Therapeutics Ltd Total Assets
Alterity Therapeutics Ltd total assets. Based on the latest financial reports, Alterity Therapeutics Ltd (ATH) holds total assets worth AU$56.92 Million AUD (≈ $40.27 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Alterity Therapeutics Ltd (ATH) total market value for the company's overall valuation and market capitalisation.
Total Assets of Alterity Therapeutics Ltd (1998–2025)
Total assets of Alterity Therapeutics Ltd from 1998 to 2025. This chart illustrates how Alterity Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See Alterity Therapeutics Ltd (ATH) stock price for real-time trading data and today's change.
Alterity Therapeutics Ltd - Asset Composition Analysis
Alterity Therapeutics Ltd Total Assets Breakdown (June 2025)
Alterity Therapeutics Ltd total assets breakdown as of June 2025. Alterity Therapeutics Ltd's total assets of AU$56.92 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 72.0% |
| Accounts Receivable | AU$3.94 Million | 8.6% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how Alterity Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Alterity Therapeutics Ltd (ATH) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alterity Therapeutics Ltd's current assets represent 99.7% of total assets in 2025, an increase from 0.0% in 1998.
- Cash Position: Cash and equivalents constituted 72.0% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
Alterity Therapeutics Ltd Competitors by Total Assets
Key competitors of Alterity Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Alterity Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 21.98 | 3.84 | 12.28 |
| Quick Ratio | 21.98 | 3.84 | 12.28 |
| Cash Ratio | 19.03 | 1.67 | 11.52 |
| Working Capital | AU$54.24 Million | AU$7.71 Million | AU$34.33 Million |
Alterity Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Alterity Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.20 |
| Latest Market Cap to Assets Ratio | 2.36 |
| Asset Growth Rate (YoY) | 139.4% |
| Total Assets | AU$46.03 Million |
| Market Capitalization | $108.75 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Alterity Therapeutics Ltd's assets at a significant premium (2.36x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Alterity Therapeutics Ltd's assets grew by 139.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alterity Therapeutics Ltd (1998–2025)
The table below shows the annual total assets of Alterity Therapeutics Ltd from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$46.03 Million ≈ $32.57 Million |
+139.42% |
| 2024-06-30 | AU$19.22 Million ≈ $13.60 Million |
-29.63% |
| 2023-06-30 | AU$27.32 Million ≈ $19.33 Million |
-33.96% |
| 2022-06-30 | AU$41.36 Million ≈ $29.27 Million |
+23.16% |
| 2021-06-30 | AU$33.59 Million ≈ $23.76 Million |
+152.43% |
| 2020-06-30 | AU$13.30 Million ≈ $9.41 Million |
-33.17% |
| 2019-06-30 | AU$19.91 Million ≈ $14.09 Million |
+6.32% |
| 2018-06-30 | AU$18.73 Million ≈ $13.25 Million |
-25.93% |
| 2017-06-30 | AU$25.28 Million ≈ $17.89 Million |
-25.04% |
| 2016-06-30 | AU$33.73 Million ≈ $23.86 Million |
-19.38% |
| 2015-06-30 | AU$41.83 Million ≈ $29.60 Million |
+0.46% |
| 2014-06-30 | AU$41.64 Million ≈ $29.46 Million |
+143.89% |
| 2013-06-30 | AU$17.07 Million ≈ $12.08 Million |
+132.55% |
| 2012-06-30 | AU$7.34 Million ≈ $5.19 Million |
-18.52% |
| 2011-06-30 | AU$9.01 Million ≈ $6.38 Million |
+32.49% |
| 2010-06-30 | AU$6.80 Million ≈ $4.81 Million |
+47.95% |
| 2009-06-30 | AU$4.60 Million ≈ $3.25 Million |
-60.79% |
| 2008-06-30 | AU$11.72 Million ≈ $8.30 Million |
+51.85% |
| 2007-06-30 | AU$7.72 Million ≈ $5.46 Million |
-25.96% |
| 2006-06-30 | AU$10.43 Million ≈ $7.38 Million |
-53.03% |
| 2005-06-30 | AU$22.20 Million ≈ $15.71 Million |
-46.07% |
| 2004-06-30 | AU$41.16 Million ≈ $29.13 Million |
+151.90% |
| 2003-06-30 | AU$16.34 Million ≈ $11.56 Million |
-7.10% |
| 2002-06-30 | AU$17.59 Million ≈ $12.45 Million |
-21.07% |
| 2001-06-30 | AU$22.29 Million ≈ $15.77 Million |
+6.76% |
| 2000-06-30 | AU$20.88 Million ≈ $14.77 Million |
+1036.48% |
| 1999-06-30 | AU$1.84 Million ≈ $1.30 Million |
+821.77% |
| 1998-06-30 | AU$199.28K ≈ $141.01K |
-- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more